New business units need to forge their own paths and adopting parent company practices is rarely the best approach.
Though the state of the global economy is gradually improving, one thing has stayed constant: organizations are looking to maximize the value of their business unit portfolio. This is no truer in any industry than Big Pharma, where main players like Johnson & Johnson and Quest Diagnostics are shedding parts of their businesses to drive revenue by dropping low-performing divisions. As this trend quickly becomes an industry norm, life sciences and pharmaceutical firms are faced with the tough decision: how to successfully manage complex divestitures and create a new entity without wreaking havoc on the existing business.
To view the full article as it appeared on Genetic Engineering & Biotechnology News, please click here.